20
Participants
Start Date
June 13, 2018
Primary Completion Date
December 31, 2024
Study Completion Date
December 31, 2024
Adempas
After obtaining baseline data, patients will be placed on oral riociguat at a dose of 0.5 mg TID which will be up titrated over two months to a maximum dose of 2.5 mg TID or maximum tolerated dose. After 3 months from onset of riociguat initiation, the University of California San Diego (UCSD) shortness of breath score, 6 Minute Walk Test (6MWD), and resting/exercise Right Heart Catheterization (RHC) will be repeated.
RECRUITING
University of Colorado, Anschutz Medical Campus, Aurora
Collaborators (1)
Bayer
INDUSTRY
University of Colorado, Denver
OTHER